Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system.

Artivion's revenue grew from $95.8M in 2024Q3 to $123.8M in 2026Q3, yet operating margin collapsed to 2.4% from 11.1% a year earlier and net margin turned to -6.4%, suggesting top-line momentum is not converting into bottom-line delivery.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.08+230.6% vs -$0.06 | $124M+2.3% vs $121M |
Q3 2026 Aug 6, 2026 | -$0.28-11300.0% vs $0.00 | $126M+4.8% vs $120M |
Q2 2026 May 7, 2026 | $0.03-50.0% vs $0.06 | $116M+0.6% vs $116M |
Q1 2026 Feb 12, 2026 | $0.05-63.6% vs $0.14 | $116M-0.4% vs $116M |
Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system.

Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
Third Quarter & Recent Business Highlights: Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the third quarter of 2026 was $(7.9) million, or $(0.16) per fully diluted share, and non-GAAP net income was $3.8 million, or $0.08 per fully diluted share Adjusted EBITDA declined 8% to $22.5 million in the third quarter of 2026 compared to $24.6 million in the third quarter of 2025 ATLANTA, Nov. 5, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. "In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.
Benchmark AORT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Artivion, Inc. (AORT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.27 | $886.89M | -50.60 | 13.59% | -3.65% | -3.93% | — | |
| $11.14 | $1.29B | -10.69 | 8.28% | -16.78% | -35.81% | — | |
| $55.02 | $2.8B | 184.20 | 14.88% | 2.52% | 2.93% | — | |
| $0.29 | $20.01M | -0.17 | 15.4% | -747.19% | -94.35% | — | |
| $93.91 | $3.25B | 26.55 | 37.13% | 19.85% | 28.38% | — | |
| $69.99 | $9.44B | 17.07 | 16.65% | 17.76% | 11.82% | — |
Artivion, Inc. (AORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Artivion, Inc. (AORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 5, 2026·SEC
Aug 6, 2026·SEC
May 18, 2026·SEC
Get notified when AORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Artivion, Inc. (AORT) stock FAQ — growth, dividends, profitability & financials explained
Artivion, Inc. (AORT) reported $481.9M in revenue over the trailing twelve months. Revenue was $441.3M in fiscal year 2025. That is 1093% more than the $37.0M of fiscal year 1996.
Artivion, Inc. (AORT) grew revenue by 14.0% over the trailing twelve months, compared with the twelve months before.
No. Artivion, Inc. (AORT) reported a net loss of $17.6M over the trailing twelve months.
Artivion, Inc. (AORT) had a return on equity (ROE) of -3.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Artivion, Inc. (AORT) had negative free cash flow of $44.4M over the trailing twelve months.